Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: A phase 1-2 study

Cancer

Volumn 116, Issue 20, 2010, Pages 4833-4839

  Momm, Felix ^a   Kaden, Markus ^a   Tannock, Ian ^b   Schumacher, Martin ^a   Hasse, Joachim ^a   Henke, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cisplatin; Gemcitabine; Nonsmall cell lung cancer; Radiochemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FATALITY; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS FEEDING; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; OXYGEN THERAPY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RADIATION SICKNESS; RESPIRATORY DISTRESS; SURVIVAL TIME; THROMBOCYTOPENIA; TRACHEA CARCINOMA; TREATMENT DURATION; CLINICAL TRIAL; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS;

EID: 78349237291     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25366     Document Type: Article

References (35)

1. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86:912-920; discussion 912-920.
2. Phernambucq EC, Spoelstra FO, Paul MA, et al. Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009;36:1052-1057.
3. Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636-648.
4. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;134:188-193. (Pubitemid 46962027)
5. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611-621. (Pubitemid 47163946)
6. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: 7-year followup of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210-1215. (Pubitemid 26302034)
7. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358-364. (Pubitemid 30111583)
8. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524-530.
9. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1535-1540. (Pubitemid 24244986)
10. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821-1826. (Pubitemid 24349383)
11. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2', 2'-difluoro-2'-deoxycytidine. Cancer Res. 2000;60:6080-6088.
12. Zhang M, Boyer M, Rivory L, et al. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 2004;58:353-360. (Pubitemid 38142459)
13. Scalliet P, Goor C, Galdermans D, et al. Gemzar (gemcitabine) with thoracic radiotherapy: a phase II pilot study in chemonaive patients with advanced non small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 1998;17:1923.
14. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723. (Pubitemid 27260108)
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;54:457-481.
16. Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol. 2009;4:845-852.
17. Benasso M, Merlano M, Sanguineti G, et al. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. Am J Clin Oncol. 2001;24:618-622. (Pubitemid 33131428)
18. Hirsh V, Soulieres D, Duclos M, et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007;2:927-932. (Pubitemid 47511596)
19. Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabine is possible with concurrent chest 3-dimensional rather than 2-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:119-127.
20. Gagel B, Piroth M, Pinkawa M, et al. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. BMC Cancer. 2007;7:112.
21. D'Angelillo RM, Trodella L, Ciresa M, et al. Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol. 2009;4:1517-1523.
22. Choy H, Jain AK, Moughan J, et al. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2009;4:80-86.
23. Vokes EE, Herndon JE Jr, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191-4198. (Pubitemid 35191021)
24. Berghmans T, Van Houtte P, Paesmans M, et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer. 2009;64:187-193.
25. Blanco R, Sole J, Montesinos J, et al. Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study. Lung Cancer. 2008;62:62-71.
26. Blackstock AW, Ho C, Butler J, et al. Phase Ia/Ib chemoradiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol. 2006;1:434-440. (Pubitemid 47181420)
27. Mornex F, Girard N. Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol. 2006;17:1743-1747. (Pubitemid 44884047)
28. Girard N, Mornex F, Douillard JY, et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer. 2010;69:86-93.
29. Leong SS, Fong KW, Lim WT, et al. A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced nonsmall cell lung cancer. Lung Cancer. 2010;67:325-329.
30. Schallier D, Bral S, Ilsen B, et al. Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:728-735.
31. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol. 2004;15:389-398. (Pubitemid 38444541)
32. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26:2457-2463.
33. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122-130. (Pubitemid 30036345)
34. Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668-1675. (Pubitemid 46595704)
35. Pottgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol. 2007;25:4987-4992. (Pubitemid 350220432)